BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes with Targeted Therapies in Real-World Cases of Colorectal Cancer

Anti-BRAF/EGFR therapy is approved for metastatic colorectal cancer (mCRC) with BRAF(V600E) mutations, although not all patients respond. Novel recent findings indicate the potential of RNF43 mutations to predict outcomes in patients with BRAF-mutated microsatellite stable (MSS) mCRC treated with an...

Descripción completa

Detalles Bibliográficos
Autores principales: Quintanilha, Julia C F, Graf, Ryon P, Oxnard, Geoffrey R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020799/
https://www.ncbi.nlm.nih.gov/pubmed/36779536
http://dx.doi.org/10.1093/oncolo/oyac265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020799/
https://www.ncbi.nlm.nih.gov/pubmed/36779536
http://dx.doi.org/10.1093/oncolo/oyac265

Ejemplares similares